EGFR and neoplasm: However, blockade of EGFR by the tyrosine kinase inhibitor gefitinib in mice displaying established colorectal tumors seemed to decrease polyp sizes, pointing to opposing roles of EGFR signaling in the resolution of intestinal inflammation and tumor growth [14].